Latest Clinic News:

• New clinical trials for patients with Parkinson's disease are open to enrollment

• The Food and Drug Administration (FDA) has approved Daxxify® (daxibotulinumtoxinA- lanm) for the treatment of cervical dystonia in adults

• Cerevel Study to Evaluate the Efficacy, Safety and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 TRIAL) - enrollment completed

• Cerevel Study to Evaluate the Efficacy, Safety and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults with Motor Fluctuations (TEMPO-3 TRIAL) - enrollment completed

• Pharma2B Study of Parkinson Disease - P2B001 had superior efficacy to its individual components and was comparable with commercially used doses of pramipexole-ER with less worsening of sleepiness and fewer dopaminergic adverse events

• LEGATO study of HD:  laquinimod significantly reduced caudate volume loss compared with placebo at week 52

• Dr. LeDoux serves his second term on the Dystonia Medical Research Foundation Medical & Scientific Advisory Council

• Exome sequencing on 1,924 patients expands genotype-phenotype correlations and engenders novel insight into the pathobiology of dystonia.